Welcome to our dedicated page for Ginkgo Bioworks Holdings SEC filings (Ticker: DNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ginkgo Bioworks Holdings, Inc. filings document an operating company focused on cell engineering, autonomous lab services, and biological R&D tools. Form 8-K reports record operating and financial results, material-event disclosures, governance matters, the completed Biosecurity divestiture, and the classification of that former business within discontinued operations.
Proxy and capital-markets filings cover board and shareholder voting matters, executive compensation, equity awards, and governance practices. The filing record also describes Ginkgo's Class A common stock listed on the NYSE under DNA, registration-statement activity, at-the-market offering arrangements, material agreements, and related capital-structure disclosures.
Ginkgo Bioworks director Henry Christian O reported two open-market sales totaling 20,000 shares of Class A common stock. The Form 4 shows a sale of 10,000 shares on 09/08/2025 at a weighted-average price of $10.92 and a sale of 10,000 shares on 09/09/2025 at a weighted-average price of $11.06. After the first sale the filing lists 34,310 shares beneficially owned and after the second sale 24,310 shares beneficially owned, both held directly. The filing includes explanations that the reported prices are weighted averages of multiple transactions within the stated price ranges.
Ginkgo Bioworks (DNA) filed a Form 144 reporting proposed and recent insider sales of Class A common stock. The filer plans to sell 2,200 shares on or about 09/10/2025 through Fidelity Brokerage Services on the NYSE, with an aggregate market value listed as $23,716.00 and total outstanding Class A shares shown as 47,089,598. The filing discloses prior acquisitions by restricted stock vesting on 10/17/2022 (1,866 shares) and 10/18/2022 (334 shares) paid as compensation, and multiple recent sales during June–August 2025 totaling 4,995 shares with gross proceeds reported on individual dates. The filer certifies no undisclosed material adverse information.
Ginkgo Bioworks Holdings, Inc. (DNA) Form 144 notifies the proposed sale of 10,000 Class A shares through Fidelity Brokerage Services with an aggregate market value of $110,599.54. The filing reports the shares were acquired on 03/11/2022 via restricted stock vesting as compensation. The approximate sale date is listed as 09/09/2025 on the NYSE, and the issuer has 47,089,598 shares outstanding. The filer disclosed a prior sale of 10,000 shares on 09/08/2025 that generated gross proceeds of $109,209.34. The notice includes the standard attestation that no undisclosed material adverse information is known.
Ginkgo Bioworks (DNA) Form 144 notice: An insider notified the sale of 10,000 Class A shares through Fidelity Brokerage Services (900 Salem St, Smithfield RI) with an approximate aggregate market value of $109,209.34. The filing lists the company’s outstanding Class A shares as 47,089,598 and an approximate sale date of 09/08/2025. All 10,000 shares were acquired from the issuer as restricted stock vesting on dates between 11/19/2021 and 03/11/2022 and were paid as compensation. The filer reports no securities sold in the past three months.
Ginkgo Bioworks Holdings entered into a Sales Agreement with Allen & Company LLC to conduct an at-the-market offering of up to $100,000,000 of its Class A common stock. Under this arrangement, Ginkgo may, at its option, sell shares from time to time through or directly to Allen as sales agent under an effective Form S-3 shelf registration and a prospectus supplement dated September 4, 2025.
The agent will use commercially reasonable efforts to execute sales and will earn a commission of up to 3.0% of the gross proceeds from each share sale. Either party can terminate the agreement with written notice. Ginkgo currently expects any net proceeds, if shares are sold, to be used for general corporate purposes, including funding operations, technology development, working capital, and capital expenditures. The company notes there is no assurance any shares will actually be issued under this at-the-market program and highlights potential dilution and other risks in its risk factor disclosures.
Ginkgo Bioworks Holdings, Inc. is offering shares of its Class A common stock with an aggregate offering price of up to $100 million. The document reports an as-adjusted net tangible book value at June 30, 2025 of $642,728,535, or $10.00 per share, which the prospectus says represents an immediate increase of $0.13 per share to existing shareholders and an immediate dilution of $1.33 per share to new investors. The prospectus supplement references the company’s filings, including the Form 10-K for the fiscal year ended December 31, 2024 filed February 25, 2025, and states that the prospectus and supplement do not contain all information in the registration statement and exhibits. The company’s corporate website is listed as www.ginkgobioworks.com.
Ginkgo Bioworks Holdings, Inc. has reached a proposed settlement to resolve several stockholder derivative lawsuits filed on the company’s behalf in federal and Delaware courts. The company entered into a Stipulation and Agreement of Settlement on May 27, 2025, and on August 21, 2025, a federal court granted preliminary approval, ordered notice to stockholders, and set a final hearing for December 18, 2025 at 1:30 p.m. PST.
If the settlement receives final court approval, Ginkgo will receive a $4,125,000 payment funded by insurance, from which plaintiffs’ counsel plans to request $2,750,000 in fees and expenses. The company will also adopt and maintain specified corporate governance and other reforms, and the plaintiffs will dismiss the derivative actions with prejudice and provide releases related to the matters alleged.
Insider transactions by Ginkgo Bioworks Holdings, Inc. (DNA): Chief Financial Officer Steven P. Coen reported vesting-related activity on August 21-22, 2025. Two sets of restricted stock units (RSUs) converted into Class A common shares: 587 RSUs and 156 RSUs were deemed acquired on August 21, 2025. A subsequent open-market sale on August 22, 2025 sold 310 shares at $12.396 each to satisfy tax withholding related to vesting. Following these transactions, the reporting person beneficially owned 11,112 and 4,847 Class A shares in the respective RSU pools, with total reported Class A holdings shown across lines. The Form 4 was signed by an attorney-in-fact on August 26, 2025.
Ginkgo Bioworks (DNA) narrowed its quarterly loss but continues to burn cash. Q2-25 revenue fell 12% YoY to $49.6 M as Biosecurity sales halved to $10.5 M, offset partly by 8% growth in higher-margin Cell Engineering to $39.1 M. Aggressive cost cuts—R&D down 60% to $53.4 M and G&A down 35% to $43.3 M—drove operating loss to $65.5 M versus $222.9 M last year. Net loss improved to $60.3 M (-$1.10 per diluted share) from $217.2 M (-$4.23).
Liquidity shifted from cash to securities. Cash & equivalents dropped 64% to $203.6 M, with $262.6 M deployed into marketable debt securities (now $270.1 M). Operating cash burn was $91.8 M versus $173.6 M a year ago. Total assets declined 11% to $1.23 B; equity fell to $613 M.
Restructuring and future obligations remain key risks. The 2024 restructuring—workforce cut >50% and facility consolidation—added $3.7 M this quarter and is expected to reach up to $29 M. A probable $24 M Google Cloud commitment shortfall looms in Aug-25, and non-refundable DNA supply payments to Twist total $11 M over 2026-27. Deferred revenue slipped 17% since year-end to $102.9 M, hinting at softer pipeline. Shares outstanding after the 1-for-40 reverse split stood at 55.4 M.